No products in the cart
Mod GRF 1-29 & GHRP-2 Blend (10mg)
Mod GRF 1-29 & GHRP-2 blend is Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Mod GRF 1-29 & GHRP-2 Peptide Blend?
Mod GRF 1-29 is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH). It is a modified version of the first twenty-nine amino acids of the naturally occurring GHRH. This modification has been suggested to provide better stability in the body and also evade metabolic clearance. It may lead to natural Growth Hormone production in the body and increased levels of IGF-1 (Insulin-Like Growth Factor-1).
GHRP-2 (Growth Hormone Releasing Peptide) is a second-generation GHRP, a type of Growth hormone Secretagogues. Other examples include GHRP-6, Ipamorelin, Hexarelin, etc. It has been studied for its potential to increase the levels of Growth Hormone in the body by amplifying the natural Growth Hormone Releasing Hormone signal transduction pathway, and suppressing the action of Somatostatin. Studies have suggested that GHRP-2 may be used in much higher doses than originally thought, while still apparently preventing the desensitization inherent to the rest of GHRPs. This may help achieve higher effective levels of Growth Hormone in the body. Another benefit of GRHP-2 over GHRP-6 is its apparent decreased appetite-stimulant effect compared to GHRP-6. It has been suggested to hold a lesser effect on gastric motility.
Various analogs of growth hormone have been studied regarding their ability to increase body Growth Hormone. Still, none of them have been proved of significant benefit as they appeared to provide only short-term effects. However, the modified GRF is a growth hormone analog that may have the potential to provide a prolonged increase in the peak and basal growth hormone levels. Like the natural Growth Hormone Release Hormone, this peptide appears to act by binding to the growth hormone-releasing hormone receptors occurring in the Pituitary gland. Researchers report that this blend may work most efficiently if administered synergistically at the same time as the body naturally releases growth hormones. A negative feedback mechanism by Somatostatin appears to regulate Mod GRF 1-29’s effect on Growth Hormone release. It may prevent unhealthy levels of Growth Hormone secretion in the body and sustain a natural pattern of growth hormone concentration. These two apparent attributes of the peptide combination provide a potential basis for preventing the usual side effects that accompany the use of artificial Growth Hormone secretagogues.
Modified GRF 1-29 Specifications
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
PubChem: CID 56841945
CAS Number: 863288-34-0
Molecular Formula: C45H55N9O6
Molecular Weight: 817.9 g/mol
PubChem: CID 6918245
CAS Number: 158861-67-7
Mod GRF 1-29 & GHRP-2 Blend Research
Researchers report GHRP-2 acts by releasing a pulse of Growth Hormone, and Mod GRF 1-29 releases and amplifies this pulse. Mod GRF 1-29 & GHRP-2 blend may provide double the effect either would have been possible to achieve alone, even in high concentrations.
Mod GRF 1-29 & GHRP-2 – Research in Fat Loss and Lean Body Mass
Increasing muscle growth is one of the widely studied potentials of Growth Hormone Analogs. It appears to increase muscle growth by increasing the size of already present muscle cells and increasing the number of muscle fibers. This is why it may be a key ingredient to building lean body mass.
Mod GRF 1-29 & GHRP-2 – Research in Tissue Repair and Anti-Aging
Most of the age-related changes occurring in the body are due to a progressive decline in the levels of Growth Hormone. This blend naturally increases GH levels that in turn may boost cellular repair and reduce cellular damage. It may enhance collagen production and fibroblast proliferation, leading to better wound healing and tissue repair after an injury. In addition, studies in these peptides suggest they may help to prevent and reverse the effects of oxidative stress on various signs of aging.
Mod GRF 1-29 & GHRP-2 – Research in Blood Sugar Level Regulation
GHRH analogs appear to play a role in blood-glucose-level regulation by enhancing cell survival and cellular proliferation of pancreatic islets in diabetic patients. They appear to up-regulate the release of Insulin-Like Growth Factors. The researchers report “short term sc administration of GHRH to healthy old men reverses age-related decreases in GH and IGF-I.” Studies have suggested a profound increase in islet size and insulin expression in rats with its use. In addition to the high blood sugar levels in people with diabetes, dyslipidemias also significantly increase the morbidity associated with diabetes. Research in GHRH analogs has suggested its potential reducing in the triglyceride-rich lipoproteins in the blood.
Mod GRF 1-29 & GHRP-2 – Research in Bone Mineral Density
GHRH analogs, through their Insulin-Like-Growth Factor 1(IGF-1) mediated actions may enhance proliferation, differentiation, and survival of bone-forming cells. This blend has the potential to increase bone mineral density and mineralization. Studies in the peptide blend also suggests that it may play a protective role against hormone-induced bone loss, such as that seen in Osteoporosis.
Mod GRF 1-29 & GHRP-2 – Research in Cardioprotection
Various studies have suggested the role of GHRH analogs in promoting the repair of cardiac tissue, improvement in heart Ejection Fraction, and reducing the infarct size following myocardial infarction. The scientists report that “Daily injection of GHRH-A improved cardiac diastolic hemodynamics, including end-diastolic pressure, end-diastolic pressure–volume ratio, and stroke work, compared to placebo.” Some laboratory studies reported a decrease in infarct size and attenuation of cardiac hypertrophy in mice. It also appears to protect the myocardial tissue from oxidative stress induced by reactive oxygen species following ischemia.
Mod GRF 1-29 & GHRP-2 – Research in Sleep
Studies have suggested the role of Mod GRF 1-29 & GHRP-2 in helping those who struggle to maintain or fall asleep. If taken before sleeping, studies have reported the peptides may help aid in the induction of sleep and the vividness of dreams.
- Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.
- Phung LT, Inoue H, Nou V, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domest Anim Endocrinol. 2000 Apr;18(3):279-91. doi: 10.1016/s0739-7240(00)00050-3. PMID: 10793268.
- Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology. 1985 Jun;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 28599
- Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992 Aug;75(2):530-5. doi: 10.1210/jcem.75.2.1379256. PMID: 1379256.
- Dubreuil P, Abribat T, Broxup B, Brazeau P. Long-term growth hormone-releasing factor administration on growth hormone, insulin-like growth factor-I concentrations, and bone healing in the Beagle. Can J Vet Res. 1996 Jan;60(1):7-13. PMID: 8825987; PMCID: PMC1263793.
- Rieger AC, Bagno LL, Salerno A, Florea V, Rodriguez J, Rosado M, Turner D, Dulce RA, Takeuchi LM, Kanashiro-Takeuchi RM, Buchwald P, Wanschel ACBA, Balkan W, Schulman IH, Schally AV, Hare JM. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):e2019835118. doi: 10.1073/pnas.2019835118. PMID: 33468654; PMCID: PMC7848727.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.